Latest Nuchev News

Nuchev Limited (ASX: NUC) has secured a final Shanghai arbitration award requiring Nouvlait to pay about RMB9.1 million, including repayment of a disputed advance, losses and interest. The award is legally effective, but Nuchev expects court enforcement may be needed and has not yet received any money.

Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Nuchev Limited has transitioned from an agency to a distribution model with H&S Global, aiming to enhance margins and scale growth across key wellness brands.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

Nuchev Limited has locked in a $2 million unsecured working capital facility from major shareholders, aiming to fuel its expansion and push towards profitability in the near term.

Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.

Nuchev Limited reported a remarkable FY25 with revenue doubling to $22.9 million, driven by strong growth in Oli6® Nutritional sales and the acquisition of bWellness. The company improved margins, reduced losses, and expanded into new international markets including Vietnam.

H&S Group has exercised performance options to increase its stake in Nuchev Limited to 48.62%, injecting $1.9 million and enhancing Nuchev’s financial flexibility for growth.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.